Axsome Therapeutics, Inc. (AXSM): Total Liabilities
$601.51M
As of 2025-12-31
$678.14M
As of 2026-06-30
+39.4%
3-year compound annual growth
+52.7%
5-year compound annual growth
n/m
10-year compound annual growth
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $601.51M | +17.6% | 2026-02-23, Balance as of period end |
| 2024-12-31 | $511.48M | +28.8% | 2026-02-23, Balance as of period end |
| 2023-12-31 | $397.26M | +79.0% | 2025-02-18, Balance as of period end |
| 2022-12-31 | $221.92M | +207.6% | 2024-02-23, Balance as of period end |
| 2021-12-31 | $72.15M | -0.3% | 2023-02-28, Balance as of period end |
| 2020-12-31 | $72.34M | +73.0% | 2022-03-01, Balance as of period end |
| 2019-12-31 | $41.83M | +189.6% | 2021-03-01, Balance as of period end |
| 2018-12-31 | $14.44M | -23.3% | 2020-03-12, Balance as of period end |
| 2017-12-31 | $18.84M | +13.2% | 2019-03-15, Balance as of period end |
| 2016-12-31 | $16.64M | +532.3% | 2018-03-07, Balance as of period end |
| 2015-12-31 | $2.63M | n/a | 2017-03-07, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| Axsome Therapeutics, Inc. (AXSM) | 2025-12-31 | $601.51M | +17.6% |
| TG Therapeutics, Inc. (TGTX) | 2025-12-31 | $415.23M | +16.9% |
| Opko Health, Inc. (OPK) | 2025-12-31 | $663.99M | -20.5% |
| Insmed Inc (INSM) | 2025-12-31 | $1.53B | -12.3% |
| Ultragenyx Pharmaceutical Inc. (RARE) | 2025-12-31 | $1.60B | +29.3% |
| Kiniksa Pharmaceuticals International, plc (KNSA) | 2025-12-31 | $196.03M | +37.9% |
| Supernus Pharmaceuticals, Inc. (SUPN) | 2025-12-31 | $390.93M | +17.6% |
| Amphastar Pharmaceuticals, Inc. (AMPH) | 2025-12-31 | $840.49M | -0.6% |
| Organogenesis Holdings Inc. (ORGO) | 2025-12-31 | $164.81M | +46.4% |
Compare AXSM, TGTX, OPK, INSM side by side · Screen every company in Pharmaceutical Preparations ↗